Volume 23, Issue 5 (1-2022)                   yafte 2022, 23(5): 1-13 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mirfakhraie R, Kuhestani Dehaghi B, Mahdizadeh M, Kazemi M H, Roshandel E. Oncolytic virotherapy, a new approach in graft-versus-host disease. yafte 2022; 23 (5) :1-13
URL: http://yafte.lums.ac.ir/article-1-3209-en.html
Hematology, Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (1921 Views)
Background: Despite recent advances in hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD) is still one of the most challenging post-transplant complications with a considerable mortality rate. Various strategies, including chemotherapy, depletion of T lymphocytes, monoclonal antibodies, corticosteroids, and other immunosuppressive drugs are used to reduce GVHD incidence, which usually increases the risk of cancer relapse and various infections in patients. The recently conducted studies have introduced oncolytic virotherapy as a promising solution to prevent GVHD and enhance the graft-versus-tumor effects. Oncolytic viruses are non-pathogenic viruses capable of selective lysis of cancer cells. These viruses can differentiate between allogeneic T lymphocytes and hematopoietic stem cells, and suppress allogeneic T cells. This review study aimed to discuss the mechanisms of oncolytic virotherapy in reducing the incidence of GVHD.
Full-Text [PDF 381 kb]   (1402 Downloads)    
Type of Study: Review article | Subject: داخلی
Received: 2021/04/7 | Accepted: 2021/11/16 | Published: 2022/03/6

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Yafteh

Designed & Developed by : Yektaweb